Narra J
Vol. 1 No. 3 (2021): December 2021

Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America

Rosiello, Dott F. (Unknown)
Anwar, Samsul (Unknown)
Yufika, Amanda (Unknown)
Adam, Rashed Y. (Unknown)
Ismaeil, Mohajer IH. (Unknown)
Ismail, Asma Y. (Unknown)
Dahman, Nesrine BH. (Unknown)
Hafsi, Montacer (Unknown)
Ferjani, Manel (Unknown)
Sami, Farah S. (Unknown)
Monib, Fatma A (Unknown)
R, Subramaniam (Unknown)
Anandu, Sunil (Unknown)
Haque, Md Ariful (Unknown)
Ferreto, Lirane ED. (Unknown)
Aburto, José TO. (Unknown)
Rojas, Jorge ET. (Unknown)
Enitan, Seyi S. (Unknown)
Yomi, Akele R. (Unknown)
Ezigbo, Eyiuche D. (Unknown)
Babadi, Elham (Unknown)
Kakemam, Edris (Unknown)
Malik, Najma I. (Unknown)
Ullah, Irfan (Unknown)
Sallam, Malik (Unknown)



Article Info

Publish Date
26 Jan 2022

Abstract

Vaccine hesitancy, defined as the reluctance or rejection in receiving a vaccine despite its availability, represents a major challenge to global health efforts aiming to control the ongoing COVID-19 pandemic. Understanding the possible factors correlated with COVID-19 vaccine hesitancy using a refined well-informed approach can be helpful to address the phenomenon. The current study aimed to evaluate COVID-19 vaccine acceptance rates using four hypothetical scenarios of varying levels of vaccine efficacy and safety profiles in ten Asian, African and South American countries. These scenarios included: 95% efficacy and 20% side effects (Vaccine A), 75% efficacy and 5% side effects (Vaccine B); 75% efficacy and 20% side effects (Vaccine C) and 50% efficacy and 5% side effects (Vaccine D). This study used a self-administered online survey that was distributed during February–May 2021. The total number of study respondents was 1337 with countries of residence as follows: India (21.1%), Pakistan (12.9%), Sudan (11.2%), Nigeria (9.3%), Iran (8.2%), Bangladesh and Brazil (7.9%), Chile (7.7%), Tunisia (7.6%), and Egypt (6.2%). The overall acceptance rates for COVID-19 vaccination were variable based on varying degrees of safety and efficacy as follows: 55.6% for Vaccine C, 58.3% for Vaccine D, 74.0% for Vaccine A and 80.1% for Vaccine B. The highest levels of COVID-19 vaccine acceptance were observed in Brazil followed by Chile across the four different safety and efficacy scenarios. The lowest COVID-19 vaccine acceptance rates were reported in Egypt and Tunisia for the low safety scenarios (20% side effects), and the low efficacy scenario (50% efficacy). The study revealed the potential effect of vaccine safety and efficacy on the intention to get COVID-19 vaccination. At the same efficacy level, higher possibility of side effects caused a large drop in COVID-19 vaccine acceptance rate. This indicates the importance of accurate communication regarding vaccine safety and efficacy on attitude towards the vaccine and intentions to get vaccinated. Regional differences in COVID-19 vaccine acceptance were observed with the Middle East/North African countries showing the lowest rates and the South American countries displaying the highest vaccine acceptance rates.

Copyrights © 2021






Journal Info

Abbrev

main

Publisher

Subject

Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Description

Narra J is a multidisciplinary journal and it is published three times (April, August, December) a year. The objective is to promote articles on infection, public health, global health, tropical infection, one health and diseases in tropics. Narra J publishes original research work across all ...